This webinar will focus on the comanagement of patients with glaucoma, specifically those who may be candidates for microinvasive glaucoma surgery procedures that target the trabecular meshwork. Michael Greenwood, MD, and Justin A. Schweitzer, OD, will discuss the ways in which they collaborate to provide the best pre- and postoperative care for these patients.
This activity is supported by an unrestricted educational grant from New World Medical.
Upon completion of this activity, the participant should be able to:
• Identify and understand the advantages and disadvantages of trabecular, supraciliary, and subconjunctival MIGS procedures.
• Describe the efficacy and safety of trabecular and Schlemm canal MIGS procedures.
• Identify the patient characteristics that favor the use of trabecular and Schlemm canal MIGS procedures.
• Adopt optimal surgical techniques when performing trabecular and Schlemm canal MIGS procedures.
This course is COPE approved for 1.0 hour of CE credit for optometrists.
Evolve is an approved COPE administrator.
COPE Course ID: 68135-GL
COPE Event ID: 119550
Dates: 2020-05-21 – 2023-05-14
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Recommended internet speed 5Mbps+
Michael Greenwood, MD
Justin A. Schweitzer, OD, FAAO
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Michael Greenwood, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Speakers Bureau: Aerie, Alcon, Allergan, Equinox, Glaukos, Johnson & Johnson Vision, New World Medical, Ocular Therapeutix, STAAR, Sight Sciences, and Zeiss; Grant/Research: Alcon, Glaukos, Ocular Therapeutix, Sight Sciences, and STAAR.
Justin A. Schweitzer, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, Johnson & Johnson Vision, Ocular Therapeutix, Reichert, Sight Sciences, and Sun Pharma; Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, and Johnson & Johnson Vision; Share/Stockholder: Equinox.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or New World Medical.